Germany, May 27 -- Circio Holding ASA, a biotechnology company developing novel circular RNA expression technology for gene and cell therapy, and AaviGen Gmbh a biotechnology company focused on precision gene therapies for human cardiac diseases, today jointly announce a research collaboration to develop circVec-enhanced AAV vectors specifically engineered for targeted, low dose heart gene therapy.By integrating these complementary technologies, the collaboration seeks to pioneer the next generation of AAV gene therapy candidates. The focus is on addressing genetic and chronic heart conditions through therapies that can be administered at low therapeutic doses, ensuring high and confined expression in heart while minimizing off-target effec...